6 Key Considerations for Safety Database Migration – More than a Handful!

Challenging the Free Migration Myth: 6 Key Considerations to Think About

When Balancing Costs and Compliance in Safety Database Migration, the notion that a safety database migration should be free is enticing but, in practice, overly simplistic. Evaluating safety database migration cost vs compliance is essential because whilst keeping costs down is indeed vital, this should not overshadow the critical aspects of ensuring compliance and maintaining data integrity.

Partnering with an experienced pharmacovigilance database migration CRO ensures that all technical and regulatory challenges are addressed efficiently. Here are six key considerations when preparing for your safety database migration:

Key Considerations for a Successful Safety Database Migration

1. The Starting Point: Where is the safety data coming from?

A single safety database? Has some safety data remained in the clinical trials safety database? Is the database validated? How up to date is the data to be transferred – are all adverse events aligned with MedDRA adverse event coding in the current version?

It is often assumed (and wrongly) that the safety data is ready for a legacy system data migration and that all data fields have been correctly allocated. Addressing data field mapping & length constraints early is critical, as constraints on safety data field lengths can cause data to be cut off, lost, or cause data transfers to crash.

So, the first thing is: check the data is ready for pharmacovigilance data transfer. We all do it when buying a car—full service history and everything functioning properly prior to purchase.

2. Comprehensive Data Transfer

Companies should ensure that all data, including non-E2B data migration items, is accurately migrated. Whilst non-E2B data migration would require additional steps to have that data imported, and therefore may result in slightly increased costs and timelines, it is important to acknowledge that these additional steps result in less time required for case clean-up and data integrity further down the line. Effectively, this results in short-term sacrifice for long-term gain during a safety database migration.

3. Regulatory Compliance

It is obvious: adherence to regulatory compliance in pharmacovigilance is paramount. Opting for the cheapest solution might (most likely) compromise your compliance, leading to potential legal and financial repercussions.

Therefore, rather than painting everything with the same brush, it is also important for your safety database validation to be compliant with your company’s specific needs. For example, if your company has the requirement for electronic gateway reporting, the usage of auto-narratives should all form part of your User Requirement Specification (URS). Balancing safety database migration cost vs compliance guarantees that your User Requirement Specification (URS) is met without compromising regulatory standing.

4. Quality Assurance

Whilst there is always the desire to complete a project in the fastest time possible, pharmacovigilance quality assurance (QA) in a safety database migration is a critical step that ensures the integrity and reliability of data post-migration.

This process involves validating the accuracy of the pharmacovigilance data transfer – ensuring no information is lost or corrupted during the transfer or processed incorrectly – and also verifies that the new system can effectively interpret and use the data. Robust pharmacovigilance quality assurance (QA) helps mitigate risks associated with data discrepancies that could lead to compliance issues or misinterpretation of safety information.

5. Technical Expertise

Leveraging skilled professionals from a pharmacovigilance database migration CRO for your safety database migration, though potentially costly, ensures a seamless transition and minimises the risk of costly errors or data loss.

These experts bring technical proficiency in both the outgoing and incoming systems, understand data field mapping & length constraints and the nuances of pharmacovigilance data, and can navigate the complexities of regulatory compliance in pharmacovigilance. Their involvement is key to avoiding disruptions in case clean-up and data integrity and safety reporting, helping to safeguard both patient safety and the company’s regulatory standing.

6. Future-proofing

Investing in scalable pharmacovigilance software and future-proofing safety databases may have initial costs, but can certainly save you money and ensure greater compliance overall.

Future-proofing safety databases accounts for the ever-evolving landscape of regulatory requirements and growing data volumes. Adopting scalable pharmacovigilance software enables companies like yours to swiftly respond to new updates in regulation, manage MedDRA adverse event coding and increasing data efficiently, and minimise the risk of future non-compliance.

Executing Your Safety Database Migration Seamlessly

These considerations highlight the necessity of a meticulous approach during a safety database migration that balances immediate expenses with long-term gains, ensuring seamless operation, regulatory adherence, and adaptability to future changes.

By acknowledging and addressing these factors, companies can achieve a successful legacy system data migration that safeguards patient safety, maintains safety database validation, and positions them for ongoing compliance and efficiency.

Whether you need automated validation via our R.A.P.T.A.R.® Reporting platform or specialized end-to-end guidance, PharSafer® provides full support. Explore our core Pharmacovigilance Services and Regulatory Intelligence solutions, or Contact Us to discuss your database transition needs.